Identification of the Major Degradation Pathways of Selumetinib

Identification of the Major Degradation Pathways of Selumetinib

Selumetinib is administered orally in capsule form and is indicated for the treatment of neurofibromatosis. To facilitate dosage adjustments, liquid preparations, such as solutions or suspensions, are to be developed. This led, first, to determine the stability profile of soluble or dispersed selume...

Full description

Bibliographic Details
Main Authors: Tahar Sif eddine Bouchema, Maxime Annereau, Victoire Vieillard, Raphael Boquet, Gisele Abreu Coelho, Florence Castelli, Audrey Solgadi, Muriel Paul, Najet Yagoubi, Philippe-Henri Secretan, Bernard Do
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceutics
Subjects:
pre-formulation studies
intrinsic stability
degradation pathways
oxidation
photooxidation
protein kinase inhibitor
Online Access:https://www.mdpi.com/1999-4923/14/12/2651

Internet

https://www.mdpi.com/1999-4923/14/12/2651

Similar Items